Literature DB >> 7676702

Review of adjuvant chemotherapy for gastric cancer.

T Nakajima1.   

Abstract

Controlled randomized studies that compared surgery alone to adjuvant chemotherapy for gastric cancer were reviewed. The amount of residual tumor after surgery, selection of drug regimens, compliance with drug administration, and trial design seem to be responsible for the success of adjuvant chemotherapy. Though there are few beneficial regimens of adjuvant chemotherapy with statistical significance, single drug therapy with mitomycin C (MMC) and combination therapy with 5-fluorouracil (5FU) and methyl-CCNU, MMC/5FU/cytosine arabinoside (MFC), and 5FU/Adriamycin/MMC (FAM) seem to have potential survival benefit for patients with curative surgery. Incorporation of new drugs into adjuvant or neoadjuvant chemotherapy might open a new aspect of multimodality therapy for gastric cancer.

Entities:  

Mesh：

Year:  1995        PMID： 7676702     DOI： 10.1007/bf00294725

Source DB:  PubMed          Journal:  World J Surg        ISSN： 0364-2313            Impact factor:   3.352


  34 in total

1.  Treatment with 5-fluorouracil in prophylaxis of relapses and metastases of stomach cancer.

Authors:  N G Blokhina; A M Garin; L V Moroz; M P Pershin; S I Chumakina; I I Gunka; A M Pantophel; N A Steklenev; M A Zirin; I N Grjaznova; A A Shain; B G Pecherskaja; N P Saveliev; N G Bashirova; V P Kuzmin; E M Budarina; E P Svedencov; K V Phateeva; I R Iunusmetov; N P Silitrin; G S Shklovskii; A N Balas; A E Ushivceva
Journal:  Neoplasma       Date:  1972       Impact factor: 2.575

2.  The use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of gastric carcinoma.

Authors:  W P Longmire; J W Kuzma; W J Dixon
Journal:  Ann Surg       Date:  1968-03       Impact factor: 12.969

3.  A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer.

Authors:  J E Krook; M J O'Connell; H S Wieand; R W Beart; J E Leigh; J W Kugler; J F Foley; D M Pfeifle; D I Twito
Journal:  Cancer       Date:  1991-05-15       Impact factor: 6.860

4.  5-fluorouracil, adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer.

Authors:  J S MacDonald; P V Woolley; T Smythe; W Ueno; D Hoth; P S Schein
Journal:  Cancer       Date:  1979-07       Impact factor: 6.860

5.  Long-term follow-up study of gastric cancer patients treated with surgery and adjuvant chemotherapy with mitomycin C.

Authors:  T Nakajima; A Fukami; I Ohashi; T Kajitani
Journal:  Int J Clin Pharmacol Biopharm       Date:  1978-05

6.  Gastric carcinoma treated by chemotherapy after resection: a controlled study.

Authors:  M Huguier; J P Destroyes; C Baschet; F Le Henand; P F Bernard
Journal:  Am J Surg       Date:  1980-02       Impact factor: 2.565

7.  Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil.

Authors:  J T Plukker; N H Mulder; D T Sleijfer; J Grond; R C Verschueren
Journal:  Br J Surg       Date:  1991-08       Impact factor: 6.939

8.  [The role of thymidylate synthetase in sequential dose of MTX and 5-FU in the advanced scirrhous type gastric cancer].

Authors:  S Akazawa; K Yoshida
Journal:  Gan To Kagaku Ryoho       Date:  1988-04

9.  Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275).

Authors:  P F Engstrom; P T Lavin; H O Douglass; K W Brunner
Journal:  Cancer       Date:  1985-05-01       Impact factor: 6.860

10.  A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. British Stomach Cancer Group.

Authors:  W H Allum; M T Hallissey; L C Ward; M S Hockey
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640
View more
  9 in total

1.  The evaluation of surgical treatment for gastric cancer patients with noncurative resection.

Authors:  Teiji Naka; Makoto Iwahashi; Mikihito Nakamori; Masaki Nakamura; Toshiyasu Ojima; Takeshi Iida; Masahiro Katsuda; Tsuji Toshiaki; Hayata Keiji; Hiroki Yamaue
Journal:  Langenbecks Arch Surg       Date:  2012-08       Impact factor: 3.445

Review 2.  Adjuvant therapy for gastric cancer: a reality at last.

Authors:  J R Hecht
Journal:  Curr Gastroenterol Rep       Date:  2000-12

3.  MLL gene rearrangement in acute myelogenous leukemia after exposure to tegafur/uracil.

Authors:  Toshihiro Fukushima; Nobuyuki Yoshio; Yutaka Noto; Hiroshi Kida
Journal:  Int J Hematol       Date:  2002-02       Impact factor: 2.490

4.  Differences in dihydropyrimidine dehydrogenase activities between gastric and colorectal cancer.

Authors:  Bunzo Nakata; Kazuya Muguruma; Shigehito Yamagata; Kiyotaka Yukimoto; Kiyoshi Maeda; Yukio Nishiguchi; Masaichi Ohira; Yasuyuki Kato; Kosei Hirakawa
Journal:  Dig Dis Sci       Date:  2004-01       Impact factor: 3.199

Review 5.  What make differences in the outcome of adjuvant treatments for resected gastric cancer?

Authors:  Toshifusa Nakajima; Masashi Fujii
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

6.  Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case.

Authors:  Chris Braumann; Goetz Winkler; Patrick Rogalla; Charalambos Menenakos; Christoph A Jacobi
Journal:  World J Surg Oncol       Date:  2006-06-24       Impact factor: 2.754

7.  Thermodynamic functions with other properties and vibrational spectra of pyrimidine ring of uracil for RNA and bio-molecule 5-aminouracil.

Authors:  J S Singh
Journal:  Heliyon       Date:  2019-12-02

8.  A DFT study of vibrational spectra of 5-chlorouracil with molecular structure, HOMO-LUMO, MEPs/ESPs and thermodynamic properties.

Authors:  J S Singh; Mohd Shahid Khan; Saeed Uddin
Journal:  Polym Bull (Berl)       Date:  2022-03-31       Impact factor: 2.870

9.  Neoadjuvant Therapy of DOF Regimen Plus Bevacizumab Can Increase Surgical Resection Ratein Locally Advanced Gastric Cancer: A Randomized, Controlled Study.

Authors:  Junxun Ma; Sheng Yao; Xiao-Song Li; Huan-Rong Kang; Fang-Fang Yao; Nan Du
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.